|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Zanthoxylum avicennae extract enhances GSK-3β to attenuate β-catenin via phosphatase 2A to block metastatic effects of HA22T cells and hepatocellular carcinoma xenografted nude mice.
|
28548306 |
2017 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Younger age (< or = 55 years; p=0.00001), hepatitis B surface antigen (HBsAg) in serum (p=0.00001), p53 mutation (p=0.008), large tumor (p=0.00001), vascular invasion (p=0.00001) and early tumor recurrence (p=0.00001) were significant associates of high AFP, while anti-HCV in serum and beta-catenin mutation in HCC had less frequent high AFP (p=0.013 and < 0.0001, respectively).
|
15305374 |
2004 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
YC-1 Antagonizes Wnt/β-Catenin Signaling Through the EBP1 p42 Isoform in Hepatocellular Carcinoma.
|
31086087 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Yap1 and β-catenin coprecipitated in hepatoblastoma but not hepatocellular carcinoma cells.
|
24837480 |
2014 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Wnt/β-catenin pathway is frequently upregulated in HCC and it is implicated in maintenance of tumor initiating cells, drug resistance, tumor progression, and metastasis.
|
26811628 |
2016 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Wnt/β-Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion.
|
25813403 |
2015 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Wnt signaling mediated by beta-catenin plays crucial roles in the development of hepatocellular carcinoma and other cancers such as colorectal cancer. beta-Catenin associates with T-cell factor (TCF) transcription factors and functions as a transcriptional activator in the nucleus.
|
12830000 |
2003 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Western blotting assay showed that overexpression of MT1H inhibited the nuclear translocation of β-catenin and that the Akt/GSK-3β axis mediated the modulatory role of MT1H on Wnt/β-catenin signaling in HCC.
|
28241806 |
2017 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
WES of the HCC tissue uncovered somatic driver mutations in the beta-catenin (CTNNB1) and nuclear-factor-erythroid-2-related-factor-2 (NFE2L2) genes.
|
25016225 |
2014 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We suggest that patients diagnosed with HCC with β-catenin mutations could be treated with an inhibitor of miR-34a.
|
25792709 |
2016 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
We studied mice with activation of β-catenin in liver (Apc<sup>ko-liv</sup> mice) and male C57Bl/6 mice given injections of diethylnitrosamine, which each develop HCCs.
|
31194980 |
2019 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
We show that in HCC but not in peritumoral tissue of the same HCC patients, Ln-5, Snail, and Slug are up-regulated, E-cadherin is down-regulated and beta-catenin is translocated into the nuclei.
|
16285938 |
2005 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
We previously identified several genes that are regulated on the overexpression of β-catenin in the HCC cell line that are suggested to be novel Wnt/β-catenin targets playing effective roles in cancer.
|
30541713 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
We previously demonstrated that the Frizzled-7 membrane receptor mediating the Wnt signalling can activate the beta-catenin pathway and promotes malignancy in human hepatitis B virus-related HCCs.
|
18577996 |
2008 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We investigated the potential role of Spry2 in HCC by expressing dominant negative Spry2 (Spry2Y55F) and activated beta-catenin (DeltaN90-beta-catenin) in the mouse liver through hydrodynamic injection and sleeping beauty-mediated somatic integration.
|
18214995 |
2008 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We investigated its function during apoptosis induced by MG132 in three hepatocellular carcinoma (HCC) cell lines, endowed (HepG2 and HuH-6) or not (HA22T/VGH) with activating mutations of beta-catenin.
|
15067380 |
2004 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
We globally investigated the molecular mechanisms of snoU2_19 in HCC and found that snoU2_19 knockdown inhibited Wnt/β-catenin signaling pathway through inducing the translocation of β-catenin in cytoplasm.
|
29654759 |
2018 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
We further found that activated β-catenin was associated with JNK pathway hyperactivation in zebrafish and in human HCC.
|
26134322 |
2015 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
We found that treatment with PGE2 significantly enhanced nuclear accumulation of β-catenin and the activation of GSK3β which could be reversed by meloxicam in HCC cells.
|
27109804 |
2016 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
We found that SPINK1 acts as a downstream effector of the CDH17/β-catenin axis in HCC.
|
28631187 |
2017 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We found a point mutation of beta-catenin in one of nine HCCs in human and a deletion of it in Hep G2 cell line.
|
10811985 |
2000 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
We exemplify its use by the analysis of five genes (CDKN2A, GSTP1, MLH1, IGF2, and CTNNB1) involved in the pathogenesis of human hepatocellular carcinoma using pools stratified for different parameters of clinical importance.
|
17690210 |
2007 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
We combined a high-fat diet with a transgenic zebrafish HCC model induced by hepatocyte-specific activated beta-catenin and assessed liver size, angiogenesis, micronuclei formation and inflammation in the liver.
|
30572006 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
We clarified genome-scale chromosomal copy number alteration profiles and mutational statuses of p53 and beta-catenin in 87 HCC tumors.
|
17983802 |
2007 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
We also confirmed linc00210 copy number gain using primary hepatocellular carcinoma (HCC) samples, and found the correlation between linc00210 CNA and Wnt/β-catenin activation.
|
29540185 |
2018 |